TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Physical Therapy Intervention in Preterm Infants During the Stay in the Neonatal Intensive Care Unit and at Home to Promote Motor Development
Brief Summary: The hypothesis of this study is that early physical therapy intervention, initiated during the NICU stay and up to 2 months corrected age, based on the family-centered model, could promote preterm infants motor development in short-term (2 months corrected age) and long-term (8 months corrected age).

There is a high evidence level of different systematic reviews, which support the effectivity of early intervention with preterm infants.

The principal aim of this randomized controlled trial is to evaluate the effectiveness of early physiotherapy intervention to promote motor development in preterm infants at 2 and 8 months corrected age.

The secondary purpose is to study the motor development of those preterm infants who received early physical therapy intervention.


Options:
A: N/A
B: Arm Label: Stockholm Preterm Interaction-Based Intervention (SPIBI); Type: EXPERIMENTAL; Interventions: Behavioral: Stockholm Preterm Interaction-Based Intervention (SPIBI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stockholm Preterm Interaction-Based Intervention (SPIBI); Assigned to Arm(s): Stockholm Preterm Interaction-Based Intervention (SPIBI)
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Physical Therapy Early Intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Physical Therapy Early Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SPEEDI_Early; Type: EXPERIMENTAL; Interventions: Behavioral: Supporting Play Exploration and Developmental Intervention (SPEEDI) | Arm Label: SPEEDI_Late; Type: EXPERIMENTAL; Interventions: Behavioral: Supporting Play Exploration and Developmental Intervention (SPEEDI) | Intervention Type: BEHAVIORAL; Name: Supporting Play Exploration and Developmental Intervention (SPEEDI); Assigned to Arm(s): SPEEDI_Early, SPEEDI_Late

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients
Brief Summary: Vascular calcification is a frequent complication in dialysis patients and is strongly associated with mortality. Its pathogenesis is complex and involves a series of markers that act on the vascular microenvironment. There is evidence that aldosterone is one of the biomarkers and may have a role in osteoinductive pathways.The aim of this study was to evaluate the effect of spironolactone, an inhibitor of mineralocorticoid receptor, in the progression of coronary calcification in patients undergoing peritoneal dialysis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: spironolactone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): spironolactone
C: Arm Label: Spironolactone group; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone 25Mg Tablet | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Spironolactone 25Mg Tablet; Assigned to Arm(s): Spironolactone group
D: Arm Label: Eplerenone; Type: EXPERIMENTAL; Interventions: Drug: eplerenone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eplerenone; Assigned to Arm(s): Eplerenone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Instrumental or Physical-exercise Rehabilitation of Balance Improve Both Balance and Gait in Parkinson's Disease.
Brief Summary: We hypothesized that rehabilitation specifically addressing balance in Parkinson ́s disease patients might improve not only balance, but locomotion as well. Two balance training protocols (standing on a moving platform, and traditional balance exercises) were compared by assigning patients to two groups: moving platform (n=15) and balance exercises (n=17). Platform moved periodically in antero-posterior, latero-lateral and oblique direction, with and without vision in different trials. Balance exercises were based on Otago Exercise Program. Both platform and exercises sessions were administered from easy to difficult. Outcome measures were: a) balancing behaviour, assessed both by index of stability (IS) on platform and by Mini-BESTest, b) gait, assessed both by baropodometry and by Timed Up and Go (TUG) test. Falls Efficacy Scale-International (FES-I) and Parkinson's Disease Questionnaire (PDQ-8) were administered. Both groups exhibited better balance control, as assessed both by IS and by Mini-BESTest. Gait speed at both baropodometry and TUG also improved in both groups. Scores of FES-I and PDQ-8 showed a marginal improvement. A four-week treatment featuring no gait training, but focussed on challenging balance tasks produces considerable gait enhancement in mildly to moderately affected patients. Walking problems in PD depend on postural instability and are successfully relieved by appropriate balance rehabilitation.


Options:
A: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo comparator | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Nicotine | Intervention Type: OTHER; Name: placebo comparator; Assigned to Arm(s): placebo
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Device: Gait Trainer 3 | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Gait Trainer 3 | Intervention Type: DEVICE; Name: Gait Trainer 3; Assigned to Arm(s): Control Group, Experimental group
C: Arm Label: Balance exercise group; Type: ACTIVE_COMPARATOR; Interventions: Other: Balance exercise | Arm Label: Mobile platform exercise group; Type: EXPERIMENTAL; Interventions: Other: Mobile platform exercise | Intervention Type: OTHER; Name: Balance exercise; Assigned to Arm(s): Balance exercise group | Intervention Type: OTHER; Name: Mobile platform exercise; Assigned to Arm(s): Mobile platform exercise group
D: Arm Label: Early Multi-Ex-PD; Type: EXPERIMENTAL; Interventions: Behavioral: Balance & Strengthening Exercises | Arm Label: Late Multi-Ex-PD; Type: EXPERIMENTAL; Interventions: Behavioral: Balance & Strengthening Exercises | Intervention Type: BEHAVIORAL; Name: Balance & Strengthening Exercises; Assigned to Arm(s): Early Multi-Ex-PD, Late Multi-Ex-PD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Italian Multicenter Randomized Phase II Study of Weekly Paclitaxel vs. Cediranib-Olaparib (Continuous vs. Intermittent) in Patients With Platinum Resistant High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief Summary: This is a Phase II, randomized, multi-centre study aiming at comparing the efficacy of Olaparib and Cediranib vs. weekly Paclitaxel in terms of progression free survival (PFS) in platinum refractory or resistant recurrent ovarian cancer.

Patients will be randomised in a 1:1:1 ratio to three treatment arms:

* Arm A: Paclitaxel 80 mg/mq every week
* Arm B: Cediranib 20 mg/day + Olaparib 600 mg / day (i.e. 300 mg BD) given every day
* Arm C: Cediranib 20 mg/day given 5 days per weeks + Olaparib 600 mg / day (i.e. 300 mg BD) given 7 days per weeks


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept, Placebo
B: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Arm B, Arm C | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm B, Arm C
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: brivanib | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: brivanib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: study of socioeconomic and demographic variables; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multi-center, Parallel Control Phase 3 Study to Compare the Efficacy and Safety of Full Human Anti-TNF Alpha Antibody (HLX03) Versus Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis
Brief Summary: This is a multicenter, randomized, double-blind, positive drug parallel-group controlled clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of HLX03 and adalimumab (Humira) in subjects with moderate to severe plaque psoriasis. This study will recruit 216 subjects (18-75 years old, male and female) with moderate to severe plaque psoriasis. The 216 subjects will be randomly assigned per 1:1 ratio into the following two treatment groups (HLX03 OR Adalimumab). The study will be conducted in three periods, including the screening period, treatment period and follow-up period. For each participating subjects, the maximal length of the study will be 56 weeks (including up to four weeks of screening time).


Options:
A: Arm Label: HLX03 group; Type: EXPERIMENTAL; Interventions: Drug: HLX03 | Arm Label: adalimumab group; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: HLX03; Assigned to Arm(s): HLX03 group | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): adalimumab group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab | Arm Label: Risankizumab 75 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for risankizumab | Arm Label: Risankizumab 150 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab 150 mg (Part A), Risankizumab 75 mg (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Risankizumab 75 mg (Part A)
D: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)
Brief Summary: The primary purpose of the study is to evaluate whether dexmedetomidine is effective in treating agitated delirium of non-intubated ICI patients


Options:
A: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol
B: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
C: Arm Label: Haloperidol; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol | Arm Label: Ziprasidone; Type: EXPERIMENTAL; Interventions: Drug: Ziprasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Haloperidol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Ziprasidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: Normal Saline (NaCl 0.9%); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): dexmedetomidine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Normal Saline (NaCl 0.9%)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Choice of Anesthesia for Endovascular Treatment of Acute Ischemic Stroke in Posterior Circulation: a Randomized Controlled Exploratory Study (CANVAS-Ⅱ)
Brief Summary: There is few randomized controlled clinical to investigated the impact of anesthetic type on outcome in patients with acute ischemic stroke in posterior cerebral circulation. It is unknown whether the choice of anesthesia is impacted on the outcomes for these patients or not. The investigators will perform a randomized controlled pilot clinical trial of general anesthesia versus local anesthesia/conscious sedation to explore and find out a potential fact whether anesthetic type alters perioperative neurological function in patients with acute ischemic stroke in posterior cerebral circulation.


Options:
A: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
B: Arm Label: Local anesthesia/conscious sedation; Type: OTHER; Interventions: Procedure: Local anesthesia/concious sedation, Procedure: Spontaneous breath | Arm Label: General anesthesia; Type: OTHER; Interventions: Procedure: General anesthesia, Procedure: Controlled ventilation | Intervention Type: PROCEDURE; Name: General anesthesia; Assigned to Arm(s): General anesthesia | Intervention Type: PROCEDURE; Name: Local anesthesia/concious sedation; Assigned to Arm(s): Local anesthesia/conscious sedation | Intervention Type: PROCEDURE; Name: Spontaneous breath; Assigned to Arm(s): Local anesthesia/conscious sedation | Intervention Type: PROCEDURE; Name: Controlled ventilation; Assigned to Arm(s): General anesthesia
C: Arm Label: general anesthesia; Type: EXPERIMENTAL; Interventions: Drug: Etomidate, Drug: Succinylcholine, Drug: Propofol, Drug: Remifentanil | Arm Label: sedation; Type: EXPERIMENTAL; Interventions: Drug: Remifentanil, Drug: Lidocaine | Intervention Type: DRUG; Name: Etomidate; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Succinylcholine; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): general anesthesia, sedation | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): sedation
D: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving In-hospital Stroke Service Utilisation (MISSION) in China: A Cluster Randomised Trial of Interventions to Shorten Door to Needle Times
Brief Summary: A cluster randomised controlled trial will be conducted, using hospital as randomisation unit. Hospitals in Zhejiang Province, China, will be randomised into two arms (1:1): an intervention arm and a control arm. Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model, whereas hospitals in the control arm will receive no intervention and maintain existing care. The randomisation will be conducted after one-year baseline data collection. The following baseline data will be used for randomisation match: hospital classification, beds in stroke centre, thrombolysis patient number, and percentage of patients receiving thrombolysis within 60 minutes of stroke onset. Hospitals with no stroke centre or with \<20 cases received thrombolysis per year will be excluded from the study. The primary outcome will be difference between intervention arm and control arm in the percentage of patients receiving thrombolysis within 60 minutes of stroke onset on the follow-up stage (post-intervention).


Options:
A: Arm Label: Interprofessional Team Approach; Type: EXPERIMENTAL; Interventions: Other: Interprofessional Team Approach | Arm Label: Usual Home Care Services; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Interprofessional Team Approach; Assigned to Arm(s): Interprofessional Team Approach
B: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention
C: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention
D: Arm Label: an intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Behaviour Change Wheel model guided intervention | Arm Label: a control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behaviour Change Wheel model guided intervention; Assigned to Arm(s): an intervention arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving In-hospital Stroke Service Utilisation (MISSION) in China: A Cluster Randomised Trial of Interventions to Shorten Door to Needle Times
Brief Summary: A cluster randomised controlled trial will be conducted, using hospital as randomisation unit. Hospitals in Zhejiang Province, China, will be randomised into two arms (1:1): an intervention arm and a control arm. Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model, whereas hospitals in the control arm will receive no intervention and maintain existing care. The randomisation will be conducted after one-year baseline data collection. The following baseline data will be used for randomisation match: hospital classification, beds in stroke centre, thrombolysis patient number, and percentage of patients receiving thrombolysis within 60 minutes of stroke onset. Hospitals with no stroke centre or with \<20 cases received thrombolysis per year will be excluded from the study. The primary outcome will be difference between intervention arm and control arm in the percentage of patients receiving thrombolysis within 60 minutes of stroke onset on the follow-up stage (post-intervention).


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention
B: Arm Label: an intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Behaviour Change Wheel model guided intervention | Arm Label: a control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behaviour Change Wheel model guided intervention; Assigned to Arm(s): an intervention arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Clinical Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Pathways; Assigned to Arm(s): 1
D: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention

Answer: B